Katarina Puco

Katarina Puco

Auto-generated profile, based on publicly available information

Katarina Puco

Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
KPKatarina Puco
Katarina Puco
GFGro Live Fagereng
Gro Live Fagereng
SBSigmund Brabrand
Sigmund Brabrand
PNPitt Niehusmann
Pitt Niehusmann
EBEgil Støre Blix
Egil Støre Blix
Åslaug HellandÅslaug Helland
Åslaug Helland
Background and purpose: In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if targeted treatments are matched with actionable genomic alterations. In the IMPRESS-Norway trial (NCT04817956), patients are treated with drugs outside the labelled indication based on their tumours molecular profile. Patients and methods: IMPRESS-Norway is a national, prospective, non-randomised, precision cancer medicine trial, offering treatment to patients with advanced-stage disease, progressing on standard treatment. Comprehensive next-generation sequencing, TruSight Oncology 500, is used for screening. Patients with tumours harbouring molecular alterations with matched targeted therapies available in IMPRESS-Norway, are offered treatment. Currently, 24 drugs are available in the study. Primary study endpoints are percentage of patients offered treatment in the trial, and disease control rate (DCR) defined as complete or partial response or stable disease in evaluable patients at 16 weeks (W16) of treatment. Secondary endpoint presented is DCR in all treated patients. Results: Between April 2021 and October 2023, 1,167 patients were screened, and an actionable mutation with matching drug was identified for 358 patients. By the data cut off 186 patients have initiated treatment, 170 had a minimum follow-up time of 16 weeks, and 145 also had evaluable disease. In patients with evaluable disease, the DCR was 40% (58/145). Secondary endpoint analysis of DCR in all treated patients, showed DCR of 34% (58/170). Interpretation: Precision cancer medicine demonstrates encouraging clinical effect in a subset of patients included in the IMPRESS-Norway trial.

23 February 2026 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
MAMaria Martin Agudo
Maria Martin Agudo
HPHenk Van der Pol
Henk Van der Pol
GSGabriel Bratseth Stav
Gabriel Bratseth Stav
TKTina Kringelbach
Tina Kringelbach
KPKatarina Puco
Katarina Puco
EHEivind Hovig
Eivind Hovig

1 January 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
KPKatarina Puco
Katarina Puco
CNCathrine S Notland
Cathrine S Notland
RSRobert Szulkin
Robert Szulkin
CJChristian Jonasson
Christian Jonasson
CBChristian Beisland
Christian Beisland
DHDaniel Heinrich
Daniel Heinrich
Purpose: In Norway, 5-year survival rates of patients with renal cell carcinoma (RCC) are increasing. The objective of this study was to describe the survival of real-world patients with metastatic RCC (mRCC) across Norway and to identify associated factors. The results may provide additional information on the benefits of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in clinical practice. Patients and Methods: We performed a longitudinal, retrospective, non-interventional cohort study using data from four national registries. The study included adults diagnosed with mRCC between 1 January 1995 and 31 December 2018. Primary endpoint was to evaluate overall survival (OS) in all included patients. Secondary endpoints included further analysis of treatment patterns and possible impact on OS. Secondary endpoint analysis was performed in patients diagnosed with mRCC between 1 January 2008 and 31 December 2018, as complete data on systemic therapies were available from 2008 and onwards. Results: In total, 4078 patients were diagnosed with mRCC in the period from 1995 to 2018. The median OS since initial mRCC diagnosis was 1.17 years. OS appeared to improve over time, 5-year OS was 10% in patients diagnosed in the period 1995– 2001 compared to 25% in 2012– 2015. The secondary analysis included 2338 patients. Fifty-five percent (55%) of the patients received systemic treatment. No differences were observed in the number of treatment lines administered over time or in the number of lines of treatment administered according to tumor histology. Among 343 patients who received ≥ 3 treatment lines, we observed longer OS in patients who received an ICI as a part of their treatment, with a median OS of 4.51 compared to 2.31 years. Conclusion: Provision of information into registries is mandatory in Norway. This retrospective, registry-based study provides real-world evidence on patient outcomes and treatments of the Norwegian patients with mRCC in the period from 1995 to 2018.

10 February 2026 in Acta Oncologica
Verified
Journal Article
Open access
KSKathinka Schmidt Slørdahl
Kathinka Schmidt Slørdahl
KPKatarina Puco
Katarina Puco
RFRagnhild Sørum Falk
Ragnhild Sørum Falk
IDIngrid Dyvik
Ingrid Dyvik
SBSigmund Brabrand
Sigmund Brabrand
Åslaug HellandÅslaug Helland
Åslaug Helland
Background and purpose: Molecular profiling guides cancer treatment, by identifying actionable genomic alterations. The IMPRESS-Norway trial (NCT04817956) is a nation-wide precision medicine trial evaluating the efficacy of approved cancer drugs on a novel indication in patients with advanced cancers harbouring potentially actionable alterations. Trametinib, a selective MEK1/2 inhibitor targeting the Mitogen-Activated Protein Kinase (MAPK) signalling pathway, is approved for BRAF V600 mutant melanoma but may also show activity in tumours with other alterations. This sub-study aimed to assess the efficacy of trametinib monotherapy across tumour types with alterations activating the MAPK signalling pathway.Patient/material and methods: In the IMPRESS-Norway trial patients are screened with the TruSight Oncology 500 panel or circulating tumour DNA profiling. Eligible patients are offered biomarker matched targeted therapies. In this subgroup analysis, we identified patients treated with trametinib monotherapy. Primary endpoints were disease control rate (DCR) after 16 weeks and safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS).Results: DCR after 16 weeks of treatment was 39% in 52 response evaluable patients, with four patients (8%) experiencing partial response, and 16 (31%) stable disease. Responses were seen in tumours harbouring BRAF fusions, GNA11, GNAQ, KRAS, NF1, and NRAS alterations, most frequently in low-grade serous ovarian cancer, central nervous system tumours, and uveal melanoma. Forty-eight percent of patients experienced treatment-related adverse events, including two treatment related deaths. Median PFS and OS were 4 and 9 months, respectively. Interpretation: Trametinib monotherapy achieved a 39% DCR in patients lacking standard options, supporting further studies to confirm efficacy and identify predictive biomarkers for treatment response.

23 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
IDIngrid Dyvik
Ingrid Dyvik
DVDaniel Vodák
Daniel Vodák
LSLaxmi Silwal-Pandit
Laxmi Silwal-Pandit
KAKristine Øverås Aasebø
Kristine Øverås Aasebø
SBSigmund Brabrand
Sigmund Brabrand
HRHege G. Russnes
Hege G. Russnes
Background: Comprehensive genomic profiling (CGP) identifies molecular alterations to support diagnosis and guide therapy in patients with cancer, yet real-world evidence on its clinical impact remains limited. We evaluated the clinical utility of equitable and population-based CGP implementation within a publicly funded healthcare system, aiming to identify actionable alterations and support treatment recommendations in patients with advanced cancer. Methods: IMPRESS-Norway is a nationwide precision medicine trial enrolling patients with treatment-refractory advanced malignancies across oncology centres. Tumour tissue was analysed using the TruSight Oncology 500 assay (TSO500, Illumina) at four regional laboratories within the Infrastructure for Precision Diagnostics (InPreD), a national programme for implementing advanced diagnostics. Results were reviewed by the national Molecular Tumour Board (MTB) to identify actionable alterations and provide biomarker-guided treatment recommendations. Findings: From April 2021 to August 2024, 1,964 patients referred for molecular profiling consented to IMPRESS-Norway, of whom 1,835 were analysed with TSO500 and evaluated by the MTB. Of these, 769 (42%) were identified with at least one actionable alteration, and 545 (30%) received a therapy recommendation through IMPRESS-Norway (24%), other clinical trials (3%), standard-of-care (2%), or off-label programmes (0·6%). The most common actionable alterations involved PIK3CA, BRAF, ERBB2, NRAS and high tumour mutational burden. Median turnaround time from requisition to MTB recommendation was 37 days (IQR 30-47). Interpretation: Nationwide implementation of CGP within a publicly funded healthcare system is feasible and supports equal access to molecular diagnostics, enabling targeted therapies and clinical trial enrolment for a substantial proportion of patients with advanced cancer. Ongoing collection of comprehensive, structured, and standardised real-world data provides evidence for clinical utility, supports translational research, and facilitates National evaluation of cost-effectiveness of CGP in routine practice.